{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:40:05Z","timestamp":1750527605949,"version":"3.41.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma (MM), a plasma cell malignancy, accounts for ~10% of hematologic malignancies and predominantly affects the older population. It exhibits a heterogeneous biology and a complex genetic phenotype that affect patient prognosis. The treatment of MM has evolved significantly over the last decade with the use of autologous stem cell transplantation and several novel agents. Consequently, outcomes have improved in this time period, with the most impact in younger patients. Management of MM in elderly frail patients requires a thoughtful approach as majority of these patients carry multiple comorbidities and are precluded from high-dose chemotherapy and autologous stem cell transplantation\u2014accounting for the more modest improvement in outcomes. Assessing transplant eligibility and performance status is a critical first step. Subsequently, the choice of frontline therapy in transplant-ineligible frail patients must balance efficacy with adverse effects to optimize quality of life. Here, we review the current state of induction regimens in this patient population.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000520","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T21:32:54Z","timestamp":1621459974000},"page":"196-200","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Induction Therapy Strategies in the Transplant-Ineligible Population"],"prefix":"10.1097","volume":"27","author":[{"given":"Narsis","family":"Attar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth K.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","year":"2020","journal-title":"Am J Hematol"},{"key":"bib2-20250621","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","year":"2020","journal-title":"J Clin"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0609.2012.01784.x","article-title":"Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era","volume":"89","year":"2012","journal-title":"Eur J Haematol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data","volume":"16","year":"2011","journal-title":"Oncologist"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jgo.2018.10.010","article-title":"Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older","volume":"10","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","year":"2016","journal-title":"Haematologica"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","year":"1987","journal-title":"J Chron Dis"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/bcj.2011.34","article-title":"Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score","volume":"1","year":"2011","journal-title":"Blood Cancer J"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","year":"2017","journal-title":"Haematologica"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma\u2014a frailty position paper of the European Myeloma Network","volume":"34","year":"2020","journal-title":"Leukemia [Internet]"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","year":"2018","journal-title":"Br J Haematol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"bib22-20250621","first-page":"24","article-title":"Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): the phase 3 MAIA Study","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"2040620719894871","DOI":"10.1177\/2040620719894871","article-title":"Daratumumab in untreated newly diagnosed multiple myeloma","volume":"10","year":"2019","journal-title":"Ther Adv Hematol [Internet]"},{"issue":"Suppl 1","key":"bib24-20250621","first-page":"864","article-title":"Phase 2 trial of daratumumab, ixazomib, lenalidomide and modified dose dexamethasone in patients with newly diagnosed multiple myeloma","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2015.223","article-title":"Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives","volume":"30","year":"2016","journal-title":"Leukemia [Internet]"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/asheducation-2016.1.495","article-title":"Sequencing of nontransplant treatments in multiple myeloma patients with active disease","volume":"2016","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","year":"2015","journal-title":"N Engl J Med [Internet]"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","year":"2019","journal-title":"N Engl J Med [Internet]"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:00:13Z","timestamp":1750525213000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000520","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"type":"electronic","value":"1540-336X"},{"type":"print","value":"1528-9117"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}